For anyone else interested, I found the patent that was being referred to and here are some quotes:
Phase 2 clinical trial mention:
"Phase 2 Clinical Study in Males with Androgenetic Alopecia(Androgenetic Alopecia)
The formulation described in Example 4b was studied in a multicenter, randomized, double-blind, phase 2 controlled study. In the study, the formulation of Example 4b (cortexolone-17α-propionate solution 5%) was compared to vehicle solution as placebo. Both the formulation containing the active and the vehicle formulation were applied twice-daily for 26 weeks in males with androgenetic alopecia (Androgenetic Alopecia). "
Example 4b:
"Anhydrous 5% w/v Solution
A 5% (w/v) solution of cortexolone-17α-propionate having the components shown in Table 6, below, was prepared by solubilizing the therapeutic agent in the mixture of solvents followed by the addition of the antioxidant (ascorbyl palmitate) and the emulsifier (polysorbate 80).
TABLE 6 Amount Amount Amount (Kg/20 (Kg/50 Component (g/100 mL) L batch) L batch)
Cortexolone-17α-propionate 5.000 1.000 2.500
Diethylene glycol monoethyl ether (TRANSCUTOL ®) 30.000 6.000 15.000
Alcohol (Ethanol) 30.000 6.000 15.000
Ascorbyl palmitate 0.500 0.100 0.250
Polysorbate 80 0.100 0.020 0.050
Propylene glycol Q.s. Q.s. Q.s. to 100 mL to 20 L to 50 L"
So for a 100ml solution they did: 5% CB-03-01, 30% Diethylene glycol monoethyl ether (TRANSCUTOL ®), 30% Ethanol, 0.5% Ascorbyl palmitate, 0.1% Polysorbate 80 and then the rest filled up with Propylene glycol which would be 34.4%. To confirm if you don't use the antioxidant (ascorbyl palmitate) and the emulsifier (polysorbate 80), the 1:1:1 rule of ethanol, PG and transcutol can apply.
Patent: https://patents.google.com/patent/U...coterone)+alopecia&oq=(Clascoterone)+alopecia